Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and...
-
Ten patients received therapy, with an initial response seen in 7 out of 9 evaluable patients to date.Responses observed in both peptide receptor radionuclide therapy-naïve and peptide receptor...
-
[212Pb]VMT-α-NET shows promise in effectively treating neuroendocrine tumorsAdministration of fractionated doses of [212Pb]VMT-α-NET shows 100% survival in a robust model of metastatic...
-
RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will have two...
-
RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- – Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will...
-
First patient with MC1R-positive metastatic melanoma treated with 212Pb-VMT01Preliminary data readout from dose escalation study expected Q4 2023 RICHLAND, Wash. & CORALVILLE, Iowa, Aug. 11,...
-
Phase I/2a clinical trials initiated: VMT-α-NET for neuroendocrine tumors, and VMT01 for melanoma. Preliminary results from initial cohorts expected by end of 2023.First patient dosed in Phase 1/2a...
-
RICHLAND, Wash. & CORALVILLE, Iowa, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company...
-
RICHLAND, WASHINGTON & CORALVILLE, IOWA, June 27, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company...
-
VMT-α-NET for neuroendocrine cancers and VMT01 for melanoma are both entering therapeutic trials under IND at leading US institutions. First melanoma patient screened and imaged with...